Back to Results

US Stem Cell Inc (USRM)

US Stem Cell, Inc. is a healthcare company focused on the research, development, and commercialization of stem cell and regenerative medicine treatments in the United States and abroad. Its development pipeline includes MyoCell, an autologous muscle stem cell therapy being prepared for Phase II/III clinical trials for heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy that has completed the IND application process for chronic heart damage and blood vessel formation support; and AdipoCell, a clinical protocol and kit being prepared for trials in chronic ischemic cardiomyopathy. In addition to its human therapeutics work, the company provides regenerative medicine solutions for veterinarians and training programs for physicians using bone marrow-derived stem cell protocols. Formerly known as Bioheart, Inc., the company adopted its current name in November 2015. It was incorporated in 1999 and is headquartered in Sunrise, Florida.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Market Cap
OTC-USRM
Not available
Not available
Not available
Weak
0.0%
0.661 K
Valuation • Fair Value

US Stem Cell Inc (OTC-USRM) Fair Value by Valuation Model

No usable valuation estimate is currently available for US Stem Cell Inc (OTC-USRM); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for US Stem Cell Inc (OTC-USRM). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for US Stem Cell Inc (OTC-USRM)

Review the profitability and growth indicators currently supported by the latest data.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review US Stem Cell Inc (OTC-USRM) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for US Stem Cell Inc (OTC-USRM)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for US Stem Cell Inc (OTC-USRM). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for US Stem Cell Inc (OTC-USRM)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for US Stem Cell Inc (OTC-USRM). No upcoming dividend amount or event date is currently available.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for US Stem Cell Inc (OTC-USRM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for US Stem Cell Inc (OTC-USRM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for US Stem Cell Inc (OTC-USRM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for US Stem Cell Inc (OTC-USRM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for US Stem Cell Inc (OTC-USRM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

US Stem Cell Inc (OTC-USRM) Stock FAQ

Data-supported answers about US Stem Cell Inc (OTC-USRM), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Weak
Current financial-health read

A reliable fair value estimate is not currently available for US Stem Cell Inc (OTC-USRM). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for US Stem Cell Inc (OTC-USRM) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for US Stem Cell Inc (OTC-USRM).

The current market capitalization listed for US Stem Cell Inc is 0.661 K.

The ticker symbol for US Stem Cell Inc is OTC-USRM, and the stock is listed on OTC Markets.

US Stem Cell Inc (OTC-USRM) is listed on OTC Markets.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B